论文部分内容阅读
化疗所致恶心呕吐(CINV)是影响肿瘤患者治疗依从性的关键因素。新型神经激肽-1(NK-1)受体拮抗剂罗拉匹坦与其他已批准上市的NK-1拮抗剂不同,可联合其他止吐药用于延迟性CINV,并能避免药物间相互作用。本文简要综述罗拉匹坦的药理作用及其在CINV治疗中的应用进展。
Chemotherapy-induced nausea and vomiting (CINV) is a key factor in the treatment adherence of patients with cancer. Unlike other approved NK-1 antagonists, the new neurokinin-1 (NK-1) receptor antagonist ropinirvan may be used in combination with other antiemetics for delayed CINV and to avoid drug-drug interactions . This article briefly reviews the pharmacological effects of rolipidean and its application in the treatment of CINV.